FOXO4-DRI: What the Research Shows About This Senolytic Peptide

What it is

As tissue ages, some cells reach a state called senescence: they stop dividing, refuse to die, and pump out inflammatory signals that damage their neighbors. Clearing those cells, an approach called senolytics, is one of the liveliest ideas in aging research (Childs et al., 2017).

FOXO4-DRI is a peptide designed for that job by Peter de Keizer’s group in the Netherlands. Senescent cells stay alive because a protein called FOXO4 holds onto p53, the protein that would otherwise order the cell to die. FOXO4-DRI is a copy of the piece of FOXO4 that does the holding, built from mirror-image amino acids so enzymes cannot digest it (the “D-retro-inverso” in the name). It floods the cell, takes FOXO4’s place, and p53 is freed to trigger self-destruction (Baar et al., 2017).

What it is studied for

Clearing senescent cells in a dish and in mice, and reversing the visible signs of aging in old mice. That is the entire list.

What the evidence actually shows

In the lab and in mice

The 2017 paper did both. In culture, FOXO4-DRI killed senescent cells at concentrations that spared healthy ones, a selectivity that matters because a senolytic that kills everything is chemotherapy. In mice, it worked in three settings: animals aged by chemotherapy regained fur and fitness; mice with a genetic fast-aging disease had their fur density, running endurance, and kidney function restored; and naturally old mice improved on the same measures (Baar et al., 2017).

By the standards of the field this was a landmark result, published in Cell and widely cited.

What has not happened since

No independent laboratory has published a replication of the mouse rejuvenation. The developers moved to a modified version for clinical development, and no human trial of FOXO4-DRI itself has been registered. Eight years on, the evidence base is still one paper. Other senolytics, the drug combination dasatinib plus quercetin, and fisetin, have reached small human trials; FOXO4-DRI has not (Kirkland & Tchkonia, 2017).

In humans

Nothing published.

From user reports

People inject it in short courses and report feeling more energetic, sometimes with joint or injection-site pain and a flu-like day afterward, which would fit a wave of cell death if that is what is happening. Nobody has measured senescent-cell burden in a user before and after.

How it works

Senescent cells depend on FOXO4 binding p53 to survive. FOXO4-DRI competes for that binding and wins. p53, released, moves to the mitochondria and starts the cell’s built-in death program. Healthy cells do not rely on the same FOXO4-p53 grip, so they are less affected, at least at the doses tested. The mirror-image construction keeps the peptide intact in the body long enough to work.

How it is used in studies

Mice received injections on three alternate days at doses that would scale to tens of milligrams in a person. Users inject 3 to 10 mg on alternate days for three doses, once or twice a year, extrapolating from the mouse schedule. No human dosing data exists. See the storage guide.

Side effects and unknowns

Reported by users: injection-site pain, fatigue, joint aches for a day or two. Documented in humans: nothing. The theoretical risks are the risks of any senolytic. Senescent cells are not purely harmful; they help wounds heal and suppress tumors in some contexts, and clearing them at the wrong time or in the wrong tissue could cost something. p53 is the most important tumor-suppressor in the body, and a peptide that manipulates it is not a molecule to treat lightly. See the safety guide.

How it compares

• Epithalon: tries to extend cells’ lives via telomerase; FOXO4-DRI removes cells instead. Opposite strategies, both mouse-only.
• MOTS-c: metabolism and mitochondria; also mouse-only.
• GHK-Cu: the one aging peptide with human trials, as a skin cream.
• Dasatinib + quercetin, fisetin: the senolytics that have reached human trials; neither is a peptide.

Legal status

Not approved anywhere. Sold as a research chemical. Not on the WADA Prohibited List.

Bottom line

FOXO4-DRI is the most dramatic single aging result in this whole category and also the thinnest evidence base: one paper, one lab, no replication, no human data. The idea behind it is sound and the field is moving, just not through this molecule. Anyone injecting it is running an experiment that the original researchers themselves have not run in a person.

References

1. Baar MP, et al. (2017). Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. PubMed
2. Kirkland JL, Tchkonia T. (2017). Cellular Senescence: A Translational Perspective. EBioMedicine. PubMed
3. Childs BG, et al. (2017). Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov. PubMed

See also

• Peptide
  GHK-Cu (Copper Peptide): Research, Mechanism, and Evidence for Tissue Repair

  GHK-Cu is a copper-carrying peptide your body makes naturally, studied mainly as a skin cream for aging skin and, in animals, for wound healing.

• Peptide
  Epithalon (Epitalon): Research, Mechanism, and a Careful Look at the Anti-Aging Evidence

  Epithalon is a four-amino-acid peptide from a Russian lab, studied for switching on telomerase and restoring melatonin. It lengthened telomeres in a dish and extended lifespan in mice, and it has never been tested for aging in people.

• Peptide
  MOTS-c: What the Research Shows About This Mitochondrial Peptide

  MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It rises with exercise, falls with age, and in mice it prevents obesity and keeps old animals fit. Human evidence is one small trial and blood-level observations.